Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BIA

- PMLiVE

Buyers’ Club wants government support on Orkambi imports

Proposes three point plan to work round impasse

- PMLiVE

Vertex eyes Duchenne market with Exonics, CRISPR deals

Biotech has gene-editing expertise

- PMLiVE

Orkambi buyers’ club set up to gain access to cheaper versions

Legal to import generics from abroad

- PMLiVE

Vertex makes choice for all-important CF triple therapy

Promises to treat up to 90% of CF patients

- PMLiVE

UK pharma’s hard-to-recruit posts need foreign recruitment boost

Post-Brexit immigration policy still unclear

- PMLiVE

NHS England wants money-back guarantee on Orkambi

Vertex resisting real-world data proposal

- PMLiVE

Still no breakthrough on Orkambi talks, MPs want answers

As other price deals go through, Orkambi stalled again

- PMLiVE

No deal or revoke looming as fourth vote on Brexit nears

Voters set to protest via EU elections, no-deal remains possibility

- PMLiVE

Novartis and Sanofi heads take on UK pharma leadership roles

Sector must fight for best Brexit outcome

- PMLiVE

Brexit clock ticking once again, UK heads for European elections

New deadline gives pharma more time, but no more clarity

Vertex: a vision of treating all CF patients worldwide draws closer

Its high prices are controversial, but Vertex also embodies the best of biopharma drug development

The Orkambi row explained

Q&A and timeline

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links